A carregar...
The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
Background: Camrelizumab (SHR1210) is a high-affinity, humanized immunoglobulin programmed cell death 1 (PD-1) monoclonal antibody. It was developed by Jiangsu Hengrui Medicine Co. Ltd. and has been approved for relapsed or refractory classical Hodgkin lymphoma patients and hepatocellular carcinoma...
Na minha lista:
| Publicado no: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7609870/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.568477 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|